- Home
- OVID vs CNTX Comparison
OVID vs CNTX Comparison
Compare OVID & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OVID | CNTX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.8M | 116.7M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | OVID | CNTX |
|---|---|---|
| Price | $1.67 | $1.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $3.50 | ★ $5.67 |
| AVG Volume (30 Days) | ★ 1.5M | 730.1K |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,610,000.00 | N/A |
| Revenue This Year | $1,077.56 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 945.89 | N/A |
| 52 Week Low | $0.24 | $0.49 |
| 52 Week High | $2.01 | $1.55 |
Technical Indicators
Market Signals| Indicator | OVID | CNTX |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 73.19 |
| Support Level | $1.59 | $1.09 |
| Resistance Level | $1.88 | $1.34 |
| Average True Range (ATR) | 0.12 | 0.13 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 66.13 | 93.97 |
Price Performance
Historical ComparisonAbout OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.